May 27, 2020
Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
May 20, 2020
Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia
May 14, 2020
Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society
May 13, 2020
Neurocrine Biosciences to Present Data from its Movement Disorder Portfolio on the American Academy of Neurology Science Highlights Platform
May 11, 2020
Alkermes Announces Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA® and VIVITROL® During COVID-19 Crisis
Apr 03, 2020
Neurocrine Biosciences Provides COVID-19 Business Update
Mar 04, 2020
Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia
Jan 28, 2020
Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder
Jan 14, 2020
ANI Announces Launch of Paliperidone Extended-Release Tablets
Jan 13, 2020
Depressive Disorders (Major Depression, Bipolar Disorder, Postpartum Depression, Treatment-Resistant Depression and Others): Pipeline Review, Developer Landscape and Competitive Insights, 2019
Jan 13, 2020
Upsher-Smith Launches Haloperidol Tablets, USP
Nov 29, 2019
Antipsychotic Drugs | World Market Analysis by Application, Drug Classification & Geography (2019-2024)
Nov 20, 2019
Depression Drugs Market Analysis by Drug Class, Disorder Type, Drug Type, Distribution Channel & Region - Forecast to 2024
Nov 19, 2019
Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder
Oct 30, 2019
Global Schizophrenia Drugs (Orals & Injectables) Market Insights, Trends and Forecasts, 2013-2018 & 2019-2023
Oct 07, 2019
Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress
Oct 04, 2019
Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress
Oct 01, 2019
Neurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress
Sep 11, 2019
The global Tourette's syndrome drugs market at a CAGR of almost 5% during the forecast period
Sep 11, 2019
Similar Response Rate but Higher Degrees of Clinical Improvement Were More Likely to Achieve With Cariprazine Compared to Risperidone - A Study by Gedeon Richter Plc